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Purpose: To identify factors that determine patients’ intentions to use point-of-care medi-
cal devices, ie, portable coagulometer devices for self-testing of the international normalized 
ratio (INR) required for ongoing monitoring of blood-coagulation intensity among patients on 
long-term oral anticoagulation therapy with vitamin K antagonists, eg, warfarin.
Methods: A cross-sectional study that applied the technology-acceptance model through a self-
completed questionnaire, which was administered to a convenience sample of 125 outpatients 
attending outpatient anticoagulation services at a district general hospital in London, UK. Data 
were analyzed using descriptive statistics, factor analyses, and structural equation modeling.
Results: The participants were mainly male (64%) and aged $ 71 years (60%). All these patients 
were attending the hospital outpatient anticoagulation clinic for INR testing; only two patients 
were currently using INR self-testing, 84% of patients had no knowledge about INR self-testing 
using a portable coagulometer device, and 96% of patients were never offered the option of 
the INR self-testing. A significant structural equation model explaining 79% of the variance in 
patients’ intentions to use INR self-testing was observed. The significant predictors that directly 
affected patients’ intention to use INR self-testing were the perception of  technology (β = 0.92, 
P < 0.001), trust in doctor (β = -0.24, P = 0.028), and affordability (β = 0.15, P = 0.016). In 
addition, the perception of technology was significantly affected by trust in doctor (β = 0.43, 
P = 0.002), age (β = -0.32, P < 0.001), and affordability (β = 0.23, P = 0.013); thereby, the inten-
tion to use INR self-testing was indirectly affected by trust in doctor (β = 0.40), age (β = -0.29), 
and affordability (β = 0.21) via the perception of technology.
Conclusion: Patients’ intentions to use portable coagulometers for INR self-testing are affected 
by patients’ perceptions about the INR testing device, the cost of device, trust in doctors/ 
clinicians, and the age of the patient, which need to be considered prior to any intervention 
involving INR self-testing by patients. Manufacturers should focus on increasing the affordability 
of INR testing devices for patients’ self-testing and on the potential role of medical practitioners 
in supporting use of these medical devices as patients move from hospital to home testing.
Keywords: oral anticoagulation, INR self-testing, technology-acceptance model, trust in doctor, 
home testing, affordability, structural equation modeling
Introduction
Technology developments present increasing opportunities for health care monitor-
ing to occur outside hospitals and clinics. However, in order to be successful, such 
initiatives have to be accepted by the potential patient population. Many conditions 
that could be self-monitored and managed remotely occur more frequently within 
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the older population, who are typically less willing to adopt 
new technology.1 This paper focuses on the example of self-
testing of blood-coagulation intensity by patients taking oral 
anticoagulation therapy (OAT) with vitamin K  antagonists 
(VKAs) such as warfarin (Coumadin). VKA therapy is 
indicated on a long-term basis in a number of medical con-
ditions, such as stroke, deep vein thrombosis, pulmonary 
embolism, heart valve surgery, and atrial fibrillation.2,3 
The limited therapeutic index of warfarin requires regular 
measuring of the international normalized ratio (INR)4 to 
avoid complications associated with either higher or lower 
blood-coagulation level.
Traditionally, the blood-coagulation level is tested 
at a hospital or clinic such as an anticoagulation clinic. 
 However, it can now be tested outside of a traditional health 
care facility – when at home or on holiday, for example – 
using a portable and handheld medical device known as a 
 “coagulometer.” In the UK, regulatory bodies have approved 
different makes and models of coagulometer devices, which 
are now commercially available.2,4 In some countries, such 
as the US, INR self-testing devices are covered by  medical/
health insurance for some medical conditions, such as heart-
valve replacement, when recommended by the general physi-
cian/practitioner (GP).5 In the UK, patients have to buy these 
devices themselves; however, the associated test strips can be 
obtained on prescription from a GP in the National Health 
Service (NHS).6
However, despite the widespread availability of portable 
coagulometer devices to facilitate INR self-testing,4 positive 
health outcomes (such as reduction in bleeding episodes 
and risk of thrombosis due to INR self-testing7), and other 
advantages, eg, freedom from visiting hospital clinics on a 
regular basis, reduction in travel and associated costs, as well 
as time savings,3 use of INR testing devices by patients at 
home remains relatively low,4,5 with most patients continuing 
to attend traditional health care settings for regular monitor-
ing of their INR levels.
In the UK, there are about 1 million patients taking OAT.4 
The exact number of self-testing patients is not known; 
however, there are anecdotal reports that the uptake of INR 
self-testing devices is not more than 1%. Patients’ low uptake 
of these devices may be due to a number of factors. For 
example, the patient’s clinical condition may render him/
her not suitable for INR self-testing; hence, the GP will not 
recommend self-testing on clinical grounds. Alternatively, 
if patients do fit the criteria for home-based testing, it may 
be that high levels of trust in, and satisfaction with, INR 
testing through a clinic/hospital and the voluntary nature 
of adopting INR self-testing leads to the opportunity being 
declined.8 Other barriers to acceptance of home INR testing 
may include the cost of coagulometer devices and associated 
test strips, a lack of awareness about INR self-testing, and a 
lack of confidence in the self-testing device.3,9
In addition, patients’ limited physical and cognitive abili-
ties, low manual dexterity, older age, literacy, and income, 
as well as negative attitudes towards the technology, which 
might include inconvenience, usability, design, and safety 
issues, can also prove to be barriers in the acceptance of the 
technology.1,10,11 Moving the focus away from the individual 
patient, there is evidence of reluctance on the part of some 
clinicians/GPs for incorporating INR self-testing as part of 
the service they deliver due to a lack of resources.12,13 There 
may also be limited ability to manage the increased initial 
workload involved in educating and preparing suitable 
patients for self-testing.12,13 Despite all these limitations, 
health care providers are expected, and compelled by the 
present regulatory and financial situation, to encourage INR 
self-testing by suitable patients.14 In this context, patients’ 
attitudes towards the process of INR self-testing and the 
INR testing devices are also important factors in shaping the 
adoption of INR self-testing.15
The aim of this research was to study patients’ intentions 
to use INR self-testing using portable coagulometer devices 
for determining blood-coagulation level. The objective was 
to identify factors determining patients’ intentions to use 
portable coagulometer devices for INR self-testing. The 
analytical framework and the model tested in our study are 
described below.
Analytical framework
In studying patients’ intentions to use point-of-care (POC) 
medical devices for INR self-testing, we applied the 
framework provided by the technology-acceptance model 
(TAM).15–17 The TAM provides the opportunity to explore 
the factors affecting the individual’s (user’s) intention to 
use (IU) a technology/device.15,16 These include the user’s 
behavioral beliefs, ie, perceived usefulness (PU),15,16,18 and 
perceived ease of use (PEOU);15,16,18 user’s characteristics, eg, 
age,19 technological self-efficacy (TSE),19 and ability to afford 
a device;20 characteristics of technology, eg, device output 
quality (DOQ),21,22 cost,23 and perceived risk;24 and external 
factors, eg, subjective norm/social influence (SN/SI),23,25,26 
and training and support.24 In addition, “trust” is an important 
independent construct in the TAM,25 and more broadly is an 
important factor in accepting/using health care technologies. 
In the field of medical care, trust can have different facets. 
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For example, patients’ trust in doctors (TID)27 could be inter-
personal trust in doctors28 or collective trust in health care 
provider institutions,29 and either of these dimensions could 
affect a patient’s willingness to accept medical advice and 
care.30 In relation to medical devices, it is perhaps most rel-
evant to frame the trust issue in terms of patients’ confidence 
that the device output/results are accurate and reliable.20,31
The TAM has been widely used in different disciplines 
including health care,31,32 where it has been mainly applied in 
relation to IT-related systems.32 In addition, some constructs 
of the TAM have also been used in studying self-monitoring 
intentions of patients with diabetes mellitus, asthma, and 
chronic obstructive pulmonary disease.33 However, thus 
far, TAM has had a limited application in studying patient 
acceptance or IU, particular POC testing (POCT) medical 
devices, such as portable coagulometers for INR self-testing. 
We chose to use the TAM due to its coverage of various 
dimensions that are relevant to the use of portable coagu-
lometer devices for INR self-testing.
Our model
In line with the TAM, we used the IU for a technology, ie, INR 
self-testing device, as the outcome (dependent) variable.15,16 
Our hypothesized direct predictors of the IU were the PU and 
PEOU,15–17 the “affordability” (cost of the device) and TID, 
and hypothesized indirect predictors of the IU were the SN/
SI, DOQ, TSE,19,23,25 age,19 affordability, and TID.
Methods
Study design
This was a cross-sectional questionnaire survey of patients 
who attended outpatient anticoagulation services at a district 
hospital in the NHS for testing of their INR levels.
Settings
This survey was conducted at an outpatient anticoagulation 
clinic at an NHS district general hospital in Greater London. 
Patients’ blood-coagulation levels are tested by drawing 
blood samples by venipuncture at the clinic, and the blood 
samples are analyzed at the central laboratory located at the 
same hospital. Patients get the test results by letter from the 
clinic, generally within 1 week of testing.
Patients’ recruitment
Patients were accessed and recruited through the antico-
agulation clinic during May–June 2010. Posters advertis-
ing the study were displayed in the clinic, and the clinic 
nurses invited all patients attending the clinic to this survey. 
The focus of the study was on patients who were unfamiliar 
with INR self-testing but were having their INR tested in the 
setting of a hospital clinic. Information was presented in the 
questionnaire about the procedure of INR self-testing using a 
handheld INR testing meter, the approximate cost of an INR 
meter to be purchased by the patient, and the availability of 
INR test strips on the NHS prescription.
In total, 350 patients were given a copy of the information 
sheet and survey questionnaire for self-completion. At the end 
of the study, 125 completed surveys were returned. No remind-
ers were issued to the nonrespondents because the researchers 
had no access to their contact details for ethical reasons.
Ethics approval
Ethics approval for this study was obtained from the 
NHS London Research Ethics Committee (reference no 
10/H0718/7, dated February 2, 2010), Research and Devel-
opment Office, Hillingdon Hospital NHS Trust (dated 
March 13, 2010), and the Research Ethics Committee, Brunel 
 University (dated March 12, 2010).
Survey questionnaire
A self-administered survey questionnaire was used to 
gather participants’ demographic information, time since 
INR testing started, knowledge about INR self-testing by a 
portable INR testing device, suggestion of INR self-testing 
by the GP/doctor, and the use of an INR self-testing device 
at home (Table 1). In addition, the survey asked patients for 
ranking of 30 items representing seven constructs of TAM, 
ie, IU, PU, PEOU, SI/SN, DOQ, TSE, and TID, taken from 
the literature (Table 2). The cost of an INR testing monitor 
was measured with affordability as a single item (Table 2). 
Finally, one open-ended question asking participants for their 
comments was also included.
Response options of the attitudinal items were ranked on 
a 7-point Likert scale:34 “strongly disagree” = 1, “moderately 
disagree” = 2, “slightly disagree” = 3, “neutral” = 4, “slightly 
agree” = 5, “moderately agree” = 6, and “strongly agree” = 7. 
The questionnaire was pilot-tested on seven patients who 
were similar with respect to the age, sex, and ethnic composi-
tion of patients taking OAT in the same locale. Following the 
pilot work, a few minor changes in wording and formatting 
were made prior to the main study.
Data analysis techniques
The data were manually entered on to the SPSS Predictive 
Analytics Software Statistics v 18 package (IBM  Corporation, 
Armonk, NY). First, we determined the  frequency statistics 
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required level of α = 0.70, thus confirming an acceptable 
reliability of the constructs.35 Thereafter, assumptions for 
multivariate data analyses such as the absence of multivariate 
outliers and the homogeneity of variance were checked and 
met before running inferential analyses.36
To identify latent dimensions, we performed an explor-
atory factor analysis (EFA) of measured TAM items (n = 26), 
excluding five items, ie, TID1 item, affordability item, and 
three items representing the IU construct. In the EFA, the 
number of extracted factors was based on Kaiser’s Eigen 
values . 1 (EVG1) criterion and breaks in the scree plot.36 
For EFA, we used the principal component analysis (PCA) 
as a factor-extraction method and the Varimax with Kaiser 
normalization as a rotation method.21 Given our sample size 
of 125, we chose a higher level of minimum factor loading, 
ie, 0.50.37 In addition, assumptions necessary for EFA such 
as the minimum participant-to-variable ratio (ie, 4:1) and 
minimum communalities $ 0.50 were applied.36
Given the limitation of the EVG1 and Scree plot criteria,38 
we conducted a parallel analysis (PA)39 using the Monte 
Carlo PCA for Parallel Analysis software40 (Ed and Psych 
Associates, State College, PA) for determining and retaining 
the number of factors in EFA.41 Thus, all components with 
initial eigenvalues (EVG1 criteria) higher than the random 
eigenvalues obtained in PA are retained.41 Comparing the 
eigenvalue results (Table 3) generated in the EFA on our 
data and the random eigenvalues generated under the PA 
(with data input: variables = 26, subjects = 125, and replica-
tions = 1000) revealed that we could only retain the first two 
factors in the EFA model for our data on the basis of eigen-
values being higher than those generated under the PA.42
Finally, using the SPSS Analysis of Moment Struc-
tures software for structural equation modeling (IBM 
 Corporation), we performed confirmatory factor analysis 
(CFA)/ structural equation modeling (SEM) to confirm/test 
our model (Figure 1). For the CFA/SEM, we employed the 
“maximum likelihood” estimation method for estimating 
the model fit. The measured items loaded on each factor 
served as indicator variables for the relevant latent factors. 
No bootstraps were used.
Results
Response rate, demographics,  
and InR testing
In this survey, the response rate was 36% (125 surveys were 
returned out of 350 distributed). Participants’ demographic 
details (Table 1) revealed that the majority of participants 
was male (64%, n = 80), aged . 70 years (60%, n = 75), 
Table 1 Participants’ demographic characteristics and international 
normalized ratio (InR) testing
 Percent Frequency
Sex
 Male 64 80
 Female 33.6 42
 Information not provided 2.4 3
Age
 18–25 years 0.8 1
 26–40 years 1.6 2
 41–55 years 9.6 12
 56–70 years 27.2 34
 71–80 years 40.8 51
 Over 80 years 19.2 24
 Information not provided 0.8 1
Highest education level
 Primary 6.4 8
 Secondary 67.2 84
 University degree 7.2 9
 Postgraduate degree 4.8 6
 Other† 12 15
 Information not provided 2.4 3
Ethnic origin
 White British 84 105
 Asian or Asian British 8 10
 Black or Black British 2.4 3
 Other‡ 3.2 4
 Information not provided 2.4 3
Time since InR tests started
 Less than 6 months 22.4 28
 6–12 months 7.2 9
 1–2 years 11.2 14
 3–5 years 22.4 28
 6–10 years 19.2 24
 More than 10 years 16.8 21
 Information not provided 0.8 1
Knowledge about InR self-testing using a handheld device
 Yes 14.4 18
 no 84.0 105
 not sure 1.6 2
Suggestion of INR self-testing by GP/doctor as something beneficial
 Yes 3.2 4
 no 96.0 120
 not sure 0.8 1
Use of InR self-testing device at home
 Yes, using it currently 1.6 2
 Yes, but given up 0.8 1
 never used 89.6 112
 Information not provided 8 10
Notes: †Technical, professional, and moderate school education; ‡Irish, Anglo-
Indian, and Jewish.
of demographics and INR testing-related variables (Table 1) 
and the descriptive statistics of all items measuring different 
constructs of the TAM (Table 2). Then, scale reliabilities of 
TAM constructs, ie, IU, PU, PEOU, DOQ, SN/SI, TSE, and 
TID constructs were checked by determining Cronbach’s 
alpha levels (Table 2), which were higher than the minimum 
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Table 2 Technology-acceptance model constructs and measured items with descriptive statistics
Construct
(item code)
Item content Mean  
values
Standard  
deviation
Construct reliability  
(Cronbach’s α)
References
Intention to use (IU) 0.71 19,21,43,44
(IU1)* Assuming that I have the chance, it is likely that I will use an InR 
handheld device at home 
3.5 2.3
(IU2) Assuming that I have the chance, I intend to use an InR handheld  
device at home
4.5 2.2
(IU3) If I have the chance, I predict that I would use an InR handheld  
device at home
4.9 2.2
Perceived usefulness (PU) 0.88 15,16,19,21
(PU1) Using an InR device would enhance my effectiveness in managing  
my health care
4.5 1.9
(PU2) Using an InR device would help me to manage (control) my  
blood-coagulation levels
4.9 2.0
(PU3) Using an InR device would support critical aspects of my health care 4.7 1.8
(PU4) Overall, an InR device would be useful in managing my health care 5.0 1.8
Perceived ease of use (PEOU) 0.94 15,16,19,21,44
(PEOU1) Learning to use an InR device would be easy for me 5.0 2.0
(PEOU2) It would be clear and understandable to use an InR device 4.7 1.8
(PEOU3) I would find it easy to measure my blood coagulation using an  
InR device
4.8 1.9
(PEOU4) It would be easy for me to become skillful at using an InR device 5.1 1.9
(PEOU5) An InR device would be clear and easy to use 4.8 1.8
Subjective norm (SN)/social influence (SI) 0.91 19,21
(Sn/SI1) The people who are important to me would think it was good  
to use an InR device at home
4.7 1.9
(Sn/SI2) My family would be supportive of me using an InR device at home 5.0 1.8
(Sn/SI3) My friends would think it was a good thing to do InR testing/use  
an InR device at home
4.7 1.8
Output quality of device (DOQ) 0.84 21,22
(DOQ1) Handheld InR devices give reliable results 4.4 1.4
(DOQ2) I believe that an InR device used at home would give accurate  
results
4.8 1.7
(DOQ3) Handheld InR devices give equivalent results to the tests  
conducted at hospital
4.5 1.4
Technological self-efficacy (TSE) 0.91 17,21,45
(TSE1) I would be able to check in the manual if something in the  
InR-testing procedure was unclear
5.2 1.9
(TSE2) I am confident that I could learn to do INR self-testing at home 5.4 2.0
(TSE3) I would be able to manage to test my blood coagulation myself  
with the InR device
4.9 2.0
(TSE4) Among my peers I am usually one of the first to try out new  
technologies
4.0 1.8
(TSE5) In general, I am not hesitant to try out new technology 4.2 2.0
(TSE6) I like to keep abreast of new technology 5.0 1.6
(TSE7) I like to experiment with new technologies 4.5 1.8
Trust in doctor (TID) 0.75 23,25,46–48
(TID1)* I know that my doctors act in my best interests 6.0 1.6
(TID2) My doctor is knowledgeable about InR testing at home 4.1 1.4
(TID3) My doctor is the best person to give me advice about the best  
way of testing my InR
5.2 1.8
(TID4) I would follow my doctor’s recommendation if s/he suggested  
that I should use a self-testing InR device at home
5.3 1.9
(TID5) My doctor is committed to my well-being 6.1 1.4
Cost of device
(Affordability) Self-testing InR devices are affordable 3.3 1.8
Notes: Rating scale: 1 = strongly disagree, 2 = moderately disagree, 3 = slightly disagree, 4 = neutral, 5 = slightly agree, 6 = moderately agree, 7 = strongly agree. *Excluded 
from inferential statistical analysis (scale reliability statistics suggested exclusion of IU1 item will increase Cronbach’s α of IU construct from 0.71 to 0.95, and TID1 item failed 
to meet requirements of homogeneity of variance).
Abbreviation: InR, international normalized ratio.
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Table 3 Initial (actual) eigenvalues generated in EFA and random 
eigenvalues generated in PA
Component/ 
factor no
Initial  
eigenvalues  
(EFA)
Random  
eigenvalue  
(PA)
Decision
1 14.691 1.9566 Accepted/retained
2 2.252 1.7980 Accepted/retained
3 1.347 1.6775 Rejected
4 1.167 1.5784 Rejected
5 0.934 1.4869
6 0.797 1.4077
Abbreviations: EFA, exploratory factor analysis; PA, parallel analysis.
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Figure 1 Confirmatory factor analysis (measurement model) and structural equation model of patients’ intentions to use international normalized ratio (INR) self-testing.
Notes: Rectangles represent measured items (endogenous variables); circles represent latent (unmeasured/exogenous) variables.
Abbreviations: d, disturbance; e, error; PEOU, perceived ease of use; TSE, technological self-efficacy; TVE, total variance extracted.
and white British (84%, n = 105). Eighty-four patients 
(67.2%) reported secondary school as the highest education 
level. Eighty-four percent (n = 105) patients had not heard 
about INR self-testing by a handheld device before this 
survey, 96% (n = 120) had not been recommended for INR 
self-testing by their GP/family doctor, and 89.6% (n = 112) 
reported that they had never used an INR testing device at 
home (Table 1).
Descriptive statistics of TAM  
items/constructs
Results of descriptive statistics of measured TAM items 
along with their respective constructs are shown in Table 2. 
The mean rankings of all measured items were $4 except the 
IU1 item (assuming that I have the chance, it is likely that I 
will use an INR handheld device at home) and affordability 
item (self-testing INR devices are affordable), which had 
mean rankings of 3.5 (±2.3) and 3.3 (±1.8), respectively 
(Table 2).
Analysis of initial scale reliabilities revealed that  Cronbach’s 
alpha reliabilities of PU, PEOU, SN/SI, and DOQ constructs 
were 0.88, 0.94, 0.91, and 0.84, respectively (Table 2). 
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The item-total statistics showed that α reliability of these 
constructs would not improve with deletion/exclusion of any 
of the measured items included in each of these constructs. 
However, item-total statistics revealed that deletion of the 
IU1 item would improve α reliability of the IU construct from 
0.71 to 0.95, deletion of TID4 would increase α reliability of 
the TID construct from 0.75 to 0.77, and deletion of TSE5 
would enhance α reliability of the TSE construct from 0.91 
to 0.94. In addition, TID1 failed to meet the requirements of 
test of homogeneity of variance (Levene’s statistics based 
on mean = 7.559, P = 0.007). Therefore, two items – IU1 
and TID1 – were excluded from further inferential statisti-
cal analyses.
Exploratory factor analysis of TAM items
Results of the EFA revealed Kaiser–Meyer–Olkin measure 
of sampling adequacy of 0.914 and Bartlett’s test of sphe-
ricity with approximate Chi-square = 747.468 (degrees of 
freedom = 28, P < 0.001), which confirmed that the data 
were suitable for EFA.36 The first run of the EFA showed a 
four-factor model; this was compared to the PA results for 
determining the number of latent factors to be retained. The 
comparison of results of Eigen values observed in EFA and 
PA suggested that we could retain only two factors (Table 3). 
Items that had cross-loadings with coefficient values . 0.35 
on more than one factor were also excluded. In the final EFA 
model, communalities extracted were between 0.70 (for 
TID5) and 0.92 (for PEOU4). Based on Kaiser’s criterion of 
EVG1, three rotations led to identification of a statistically 
significant model with two latent factors, which extracted 
82.2% of total variance in the model. The rotated component 
matrix (Table 4) showed that six measured items were loaded 
on factor 1. These included three items – PEOU1, PEOU3, 
and PEOU4 – representing the PEOU construct and three 
items – TSE2, TSE3, and TSE6 – representing the TSE con-
struct. Based on the nature of the loaded items, we named 
factor 1 the “perception of technology.” Factor 1 explained 
62.7% of the extracted variance in the model (Table 4). The 
rotated component matrix also revealed that factor 2 was 
loaded with two items, TID3 and TID5, which was deemed 
to represent the construct of TID. Factor 2 contributed in 
extraction of 19.4% of the variance in the model (Table 4).
Results of EFA also revealed that all measured items 
retained in the final model had communalities $ 0.70 and 
their loadings on the main factor were $0.77, while their-
cross loadings on the other factor were #0.30. Cronbach’s 
alpha coefficients for both latent factors were determined 
(Table 4).
Confirmatory factor analysis/structural 
equation modeling of TAM items
Results of the CFA, also known as the measurement model, 
and the SEM confirmed a statistically significant model 
 (Figure 1). The goodness-of-fit measures obtained for the 
model were within the recommended limits, which revealed 
a good fit of the model with the given data (Table 5).
Results of standardized regression weights/loadings (β) 
of measured variables and latent constructs are shown in 
Figure 1. The results of standardized loadings revealed that 
the major determinant of patients’ IU for INR self-testing 
was perception of technology (β = 0.92, P < 0.001). In addi-
tion, TID had a significant but negative effect (β = -0.24, 
P = 0.028), and affordability had a significant and posi-
tive effect (β = 0.15, P = 0.016) on patients’ IU for INR 
Table 4 Exploratory factor analysis showing factors with loadings, communalities (h2), variance extracted, and scale reliability of latent 
factors of patients’ acceptance of international normalized ratio (InR) self-testing device
Item code – content Loadings Communalities
Factor 1 Factor 2 h2
PEOU1 – Learning to use an InR device would be easy for me 0.936 0.214 0.811
PEOU4 – It would be easy for me to become skillful at using an InR device 0.933 0.057 0.874
TSE2 – I am confident that I could learn to do INR self-testing at home 0.920 0.187 0.922
PEOU3 – I would find it easy to measure my blood coagulation using an INR device 0.914 0.146 0.881
TSE3 – I would be able to manage to test my blood coagulation myself with the InR device 0.898 0.075 0.857
TSE6 – I like to keep abreast of new technology 0.830 0.243 0.747
TID3 – My doctor is the best person to give me advice about the best way of testing my InR 0.002 0.882 0.779
TID5 – My doctor is committed to my well-being 0.308 0.779 0.702
Eigenvalues  5.322 1.251
Average variance explained (%) 62.72 19.44
Cronbach’s α reliability 0.96 0.59
Notes: Extraction method, principal component analysis; rotation method, varimax with Kaiser normalization; rotation converged in three iterations.
Abbreviations: PEOU, perceived ease of use; TID, trust in doctor; TSE, technological self-efficacy.
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 self-testing (Figure 1). Moreover, results showed an indirect 
effect of TID (β = 0.40), age (β = -0.29) and affordability 
(β = 0.21) on IU for INR self-testing through the perception 
of technology. Overall, the model showed that all the afore-
mentioned predictors explained 79% of the variance in the 
IU for INR self-testing (Figure 1).
Results also showed that perception of technology was 
significantly and positively affected by TID (β = 0.43, 
P = 0.002) and affordability (β = 0.23, P = 0.013), as well 
as significantly but negatively affected by age of the patient 
(β = -0.32, P < 0.001). All these three variables explained 
34% of the variance in the perception of technology construct 
(Figure 1).
Construct (composite) reliabilities (CR) and average 
variance extracted (AVE) for latent factors used in the CFA/
SEM model were also calculated.37 Results revealed that the 
perception of technology had CR = 0.96 and AVE = 80.43%, 
TID had CR = 0.67 and AVE = 70.55%, and IU for INR 
self-testing had CR = 0.93 and AVE = 93.4%. These values 
of CR and AVE revealed adequate internal reliabilities and 
convergent reliabilities of these factors/constructs.
Patients’ free comments on InR  
self-testing and related issues  
(qualitative data)
Forty-one (32.8%) patients provided open-ended comments 
in relation to INR self-testing. The main issues highlighted in 
these comments (Table S1) were regarding INR self-testing in 
general, eg, “Home testing INR is a good idea” and “I never 
knew you could do this [INR testing] at home. I think infor-
mation should be available at the clinic” (Table S1,  section 
A); INR testing device cost, eg, “Will patients have to buy 
their own device? Sensible idea, pity about the costs” and “I 
would not mind buying a machine if they were less expen-
sive” (Table S1, section B); access and use, eg, “Have no 
experience of home devices […] tell us more” (Table S1, 
section C); hospital outpatient anticoagulation services, eg, 
“Hospital provides good service” and “Although sometimes 
awkward to attend clinic, but does keep you in touch with 
health matters, general gossip and a reason to get out and 
exercise” ( Table S1, section D); outpatient anticoagulation 
clinic staff, eg, “Visiting the clinic is a very interesting experi-
ence with all staff making you welcome … reassuring at all 
times … answering any questions … all staff have time to 
explain even small requests … something handheld device 
cannot do” (Table S1, section E); patients’ comorbidities, 
eg, “I have diabetes, a DVT [deep vein thrombosis], a bad 
back, and wobbly left hand and had triple bypass … so not 
pleasant to spend a morning and walk down to the clinic” 
(Table S1, section F); and limitations and illnesses, eg, “INR 
device … unsuitable for me as I am 90 years, and visually 
impaired” (Table S1, section F).
Discussion
Self-testing of INR is suggested only to those patients who 
fulfill self-testing criteria recommended by professional bod-
ies.49,50 Results of our study have revealed that only a small 
minority, ie, three patients in this sample, were suggested 
INR self-testing by their GPs, and two of those patients 
were currently self-testing their INR. This finding is in line 
with previous literature that suggested that the number of 
INR self-testers is very low, although of course the strong 
representation of older people in the sample may go some 
way to explain this.
Our findings regarding the demographic characteristics 
(Table 1) and comorbidities (Table S1, section F) among 
outpatients attending hospital outpatient anticoagulation 
services have revealed these patients are mostly older people 
with multiple illnesses, such as DVT and pulmonary emboli, 
requiring VKAs on a long-term basis, which is in agreement 
with other studies.2,3 The majority of participants were not 
familiar with INR self-testing devices, and they had been 
visiting hospital anticoagulation services for their INR testing 
for at least several months (Table 1). These patients’ responses 
vis-à-vis performing INR self-testing must therefore be 
considered in the context of their experience of INR testing 
in hospital outpatient settings.
The comments that participants provided suggest that 
some patients may not have been considered suitable 
for INR self-testing due to multiple illnesses and severe 
Table 5 Goodness-of-fit indices observed in the confirmatory factor analysis and structural equation model
χ2 Df Sig (P) χ2/df GFI RMSEA NFI CFI AGFI Reference
Recommended values .0.05 #3.00 $0.9 #0.08 $0.9 $0.9 $0.9 48
Observed values  
in this model
58.453 50 0.193 1.169 0.903 0.043 0.941 0.991 0.849
Abbreviations: AGFI, adjusted goodness-of-fit index; CFI, comparative fit index; Df, degrees of freedom; GFI, goodness-of-fit index; NFI, normated fit index; RMSEA, root 
mean square error of approximation; Sig, significance level (P).
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 physical limitations and impairments (Table S1, sections 
F and G). Nevertheless, some participants were interested 
in INR self-testing (Table S1, section A). Apart from the 
nature of comorbidities and impairments (Table S1,  sections 
F and G), the main barriers for INR self-testing by these 
patients included the cost of an INR testing meter that was 
adjudged unaffordable (Table S1, section B). It seemed that 
satisfaction with the hospital anticoagulation services and 
clinic staff (Table S1, sections D and E) who provided reas-
surance (Table S1, section E) and a human touch (Table S1, 
section C) also rendered INR self-testing at home as a less 
attractive option.
Turning to the analysis of the quantitative data, our find-
ings of a statistically significant structural equation model 
of patients’ IU for INR self-testing revealed that apart from 
patients’ perception of technology (ie, INR self-testing 
device), patients’ TID, affordability, and age significantly 
affected (determined 79% variance) participants’ intentions 
to use INR self-testing. The main findings vis-à-vis our 
model and the main factors affecting INR self-testing are 
discussed below.
InR self-testing and the TAM
In the present study, we have identified factors that sig-
nificantly contribute to predictions of patients’ IU for INR 
self-testing. This has been done within the frame provided 
by the TAM, previously applied for studying acceptance of a 
range of technologies.31 The present study is the first, to our 
knowledge, that has sought to study the TAM with respect to 
patients’ acceptance of portable INR-testing devices.
It is notable that our survey did not obtain the generally 
expected structure of the TAM. We can surmise that there are 
at least two possible reasons for this. First, although some 
of the survey participants knew about coagulometer devices 
in principle, the fact that, by definition, the majority had no 
day-to-day experience in practice of them, we would argue, 
is less likely to enable a clear differentiation and result in 
significant relationships between TAM constructs.51 Secondly, 
it is quite possible that the applicability of the TAM is limited 
in relation to acceptance of medical devices, especially for 
self-testing by patients, and especially the older people with 
chronic diseases. Previous work in the area of the TAM, even 
within health care, has, as outlined earlier, focused on infor-
mation technologies. Further work to clarify this and thus to 
explore further the potential of the TAM around acceptance 
of self-testing medical devices is required.
However, our study identified two constructs, ie, percep-
tion of technology and TID, that significantly contributed 
to our model of acceptance of portable INR testing devices, 
which was operationalized as IU for INR self-testing. In 
addition, we have identified that affordability has a significant 
relationship with IU for INR self-testing. We discuss these 
findings below by focusing on the constructs and variables 
that comprised our model (Figure 1).
Perception of technology
In our survey, perception of technology emerged as an 
important factor, which included six items that measured 
two things: (1) PEOU and (2) TSE of the respondent (user). 
PEOU is one of the core constructs in the TAM and it mea-
sures participants’ attitudinal beliefs about the technology, 
while the TSE of the respondent (user) contributes in the 
PEOU construct.17,18 However, in our data, it was not possible 
to separate PEOU and TSE, and they loaded on one factor. 
In addition, there was no role for the PU factor, which is 
usually an important construct in the TAM.15–17 The reason 
for this is unclear. It may be the case that patients could not 
envisage the usefulness of INR self-testing possibly due to a 
general satisfaction with hospital-based testing, or they may 
have been reluctant to report a PU in case this was seen as 
an indication of their interest in self-testing.
We found that perception of technology is the main 
determinant of these patients’ IU for INR self-testing. 
 Unsurprisingly, our results show that IU for a self-testing 
device is higher when there is a higher and positive perception 
about the device. In addition, our results also revealed that 
the effect of perception of technology on the IU for INR self-
testing had indirect contributions from TID,  affordability, 
and age. Contributions of these factors both indirectly via 
the perception of technology and directly on the IU for INR 
self-testing are discussed below.
Trust in doctor
Our results show that TID has both a direct and an indirect 
effect on patients’ IU for INR self-testing. The direct effect 
of TID on IU for INR self-testing was significantly negative, 
that is, that those with high levels of trust in their doctor had 
less intention to conduct self-testing. One reason for the nega-
tive effect of TID on these patients’ IU for INR self-testing 
could be a reflection of their satisfaction with the current 
practice of their INR testing by a health care professional at 
outpatient anticoagulation clinics, and the nature of some of 
the comments made by patients (Table S1, sections D and E) 
gives credence to this possibility. In hospital outpatient 
clinic-based INR testing, there are opportunities for the 
patients to meet and discuss issues related to their illness 
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and INR levels with the clinic staff (Table S1, point E.2), 
as well as exchange experiences and socialize with other 
patients (Table S1, point D.5) with similar health concerns.52 
Thus, high TID may be strongly anchored in the experience 
of hospital testing and the benefits this is perceived to bring. 
TID may thus not be transferred into the imagined experience 
of home testing, plus of course we know that home testing 
had not been recommended by the GP for these patients. The 
other influencing factor in this regard is respondents’ age, 
as the majority of patients in our study were aged 71 years 
or more, which has a negative effect on the acceptance of 
technology in general.10 It would be interesting to investi-
gate acceptance of the scenario of home-based INR testing 
carried out by a health care professional, eg, a nurse, using 
a portable INR-testing device, representing as it does the 
continued involvement of health care professionals but within 
the context of the home.
We also found that TID has a significant and positive 
effect on perception of technology, which was positively 
related to IU for INR self-testing. This could be indicative of 
two alternative “routes” with which patients are faced, which 
may be more or less salient at any single point in time. On the 
one hand, where patients are largely satisfied with their doctor 
and trust the provision of outpatient anticoagulation services 
that the doctor has commended, this trust will thus be linked 
to a rejection of the suggestion of alternative INR-testing pro-
vision (eg, via self-testing). On the other hand, it may be the 
case that where the trusted doctor’s communication focuses 
on or perhaps triggers a positive perception of the self-testing 
device (eg, positive perception of technology), under these 
circumstances there is greater IU for the device.
These findings therefore might suggest that doctors can 
play a pivotal role in the adoption of POCT medical devices 
for INR self-testing and that there is value in particularly 
encouraging a positive perception of self-testing medical 
devices for certain types of patients, such as the older patients 
with chronic and multiple illnesses. Doctors have an integral 
role in recommending use of POCT medical devices for INR 
self-testing, and this finding is important for medical device 
manufacturers that might see little or no role for clinicians in 
their push for home-use medical devices and therefore focus 
their marketing efforts on patients or their caregivers.
Affordability
When we explored the relationship between affordability and IU 
for INR self-testing, our results showed that affordability had 
a direct and significantly positive effect: the more  affordable it 
was seen to be, the greater the intention to conduct self-testing. 
There was also an indirect effect on intention (β = 0.21) via 
perception of technology. The findings suggest that afford-
ability is an important factor for patients with regard to INR 
meters for self-testing.
The open-ended comments of patients showed that these 
patients saw the cost of an INR-testing device as a barrier in 
their INR self-testing, and the device cost was seen as too 
high and beyond their means (Table S1, section B). This was 
also reflected in the low mean rating for the affordability item 
(Table 2). The cost of coagulometer devices and test strips, 
unless covered by the insurance or health care provider, is 
likely to be a decisive factor in INR self-testing by some 
types of patients, such as those who are unemployed, on 
low incomes, and retired people. Consequently, adoption of 
INR self-testing is low in health care systems such as the 
NHS, where the cost of the device is not reimbursed and 
the patients have to bear the cost. In such situations, about 
half of the eligible patients might decline to perform INR 
self-testing due to cost.53 In contrast, acceptance of INR self-
testing is higher in health care systems in countries such as 
Germany, where the cost of the device and test strips is fully 
reimbursed.53 In addition, INR self-testing is reported to be 
more expensive than conventional hospital/clinic-based INR 
testing,54 which is mainly due to high costs of portable INR-
testing devices and test strips.3,4,49 Therefore, the cost of test-
ing equipment could be one of the major barriers in the wider 
adoption of INR self-testing.9 Arguably, while technologies 
are not considered as affordable, there is little engagement 
with their potential benefits, and this in turn affects IU. The 
manufacturers of portable coagulometer devices, and health 
care providers recommending the use of these devices, should 
take note of the affordability/high cost of the devices and 
related materials such as test strips.
Age
Our findings show that the age of the patient has a significant 
but negative effect on the perception of technology and through 
that age has an indirect and negative effect (β = -0.29) on IU for 
INR self-testing: younger patients have more positive percep-
tions about self-testing medical technology. This finding is in 
agreement with previous literature, which suggests that technol-
ogy acceptance is lower in older people compared to younger 
people.1,10 Therefore, our findings suggest that younger patients 
are more likely to accept self-testing medical devices such as 
portable coagulometer devices for INR self-testing.
Overall, our results have shown that perception of tech-
nology, TID, affordability, and age are important factors that 
have a significant effect on patients’ IU for INR self-testing 
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using portable coagulometer devices. Our results have also 
shown limitations of the TAM in its present format to predict 
patient’s IU for POCT medical devices for INR self-testing.
Study limitations
We recognize the limitations of the study. First, the sample 
size is relatively small, although as noted earlier it was large 
enough to allow the legitimate use of multivariate analysis 
techniques. Second, the response rate achieved (about 36%) 
was relatively low; however, this is in line with other stud-
ies involving older patients with chronic illnesses.55 Third, 
participants were from only one NHS primary care trust, and 
they used anticoagulation services at the same district general 
hospital. Fourth, only three participants in our sample had 
any experience of INR self-testing, and the findings of this 
study must be interpreted recognizing that participants were 
responding in the light of the information they were provided 
about INR self-testing and against the backdrop of their own 
experiences of INR testing within the context of the hospital 
where the test was administered by health professionals. Care 
should be taken in generalizing the results of this study to 
other types of home-use medical devices. The results are 
most applicable when considering the use of self-testing for 
those patients who already have their INR monitored within 
the hospital context.
Despite the aforementioned limitations, this is the first 
study that has applied the TAM in studying patients’ IU for 
portable coagulometer devices for INR self-testing. However, 
our findings should be interpreted with caution, as stated 
earlier, and we suggest further research to confirm or reject 
the model that has emerged in our study.
Conclusion
Factors affecting patients’ IU for portable medical devices 
for INR self-testing (home testing) are different from the fac-
tors that affect acceptance of other technologies. Important 
determinants of patients’ IU for INR self-testing include 
patients’ perceptions about the INR-testing devices, the cost 
of these devices, TID, and the age of the patient. Health care 
service providers and medical device manufacturers need to 
consider the importance and contributions of these factors in 
patients’ adoption of INR self-testing, especially by patients 
previously tested in the hospital context.
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Table S1 Qualitative data: patients’ comments on international normalized ratio (InR) testing
A. INR self-testing 
A.1 “Home-testing InR is a good idea.” 
A.2 ‘‘I would love […] to test my own blood.” 
A.3  “I have been attending appointments for 6 months taking blood tests […] I would like to […] do my own blood tests at home […] I feel I have 
been left by the hospital services to just get on with it and have had no advice or help.”
A.4 “I would like home-testing as driving and parking is getting more and more difficult and expensive!!” 
A.5 “I never knew you could do this [InR testing] at home. I think information should be available at the clinic.” 
A.6 “Performed InR self-testing but given up.” [no reasons reported.] 
A.7  “I would really like to try this. I am a nurse […] I will be on warfarin for the rest of my life due to recurrent PEs [pulmonary emboli] and DVTs 
[deep vein thromboses].”
B. INR-testing device cost 
B.1 “Will patients have to buy their own device? Sensible idea, pity about the costs.” 
B.2 “I would not mind buying a machine if they were less expensive.” 
B.3 “The price is a deterrent.” 
B.4 “I know nothing about the InR device […] certainly could not afford £ […] for one.” 
B.5 “As a diabetic, I test [blood sugar level] regularly […] these tests are about 10% of the cost quoted for an InR meter.” 
B.6 “InR testing device is not affordable at the current price.” 
B.7 “[The device] price would deter me.” 
C. INR-testing device access/use 
C.1 “Have no experience of home devices […] tell us more.” 
C.2 “I spoke to the nurse about this but received no encouragement.” 
C.3 “How would you obtain advice regarding warfarin dosage if the InR was [slightly] different from last test?” 
C.4 “I prefer the human touch to some inanimate object that I may not even know is accurate!” 
C.5 “not having InR testing machine on [nHS] prescription.” 
C.6 “I have never seen the [InR] device.” 
C.7 “I would not be happy carrying out my own InR.” 
C.8 “I would panic if bleeding occurred while I did InR testing.” 
C.9  “I purchased my own [INR testing] monitor. Good but not always true to hospital results. Both work well but confidence not wholly in the 
machine results.”
D. Hospital anticoagulation services 
D.1 “Visiting hospital every month was not a problem.” 
D.2 “Hospital provides good service.” 
D.3 “Occasionally have to phone [clinic] for results.” 
D.4 “Trips to […] hospital are very taxing.” 
D.5  “Although sometimes awkward to attend clinic but does keep you in touch with health matters, general gossip and a reason to get out and 
exercise.”
E. Anticoagulation clinic staff 
E.1 “The staff there were excellent.” 
E.2  “Visiting the clinic is a very interesting experience with all staff making you welcome […] reassuring at all times […] answering any questions […] 
all staff have time to explain even small requests […] something handheld device cannot do.”
E.3 “I cannot see that a home tester would relieve my concern and I would have to check with doctor or hospital every month.” 
E.4 “The team at […] hospital are great. I look forward to my visits about once a month. They are very efficient and treat you like people.” 
F. Patient illness and comorbidities 
F.1  “I have diabetes, a DVT, a bad back, and wobbly left hand and had triple bypass […] so not pleasant to spend a morning and walk down to the clinic.”
F.2 “I have muscular degeneration […] I have stopped taking my blood samples with the diabetic device.” 
F.3 “I will be on warfarin for the rest of my life due to recurrent PEs and DVTs.” 
G. Patient limitations 
G.1 “InR device […] unsuitable for me as I am 90 years, and visually impaired.” 
G.2 “I have had stroke and have use of one hand only […] I have home visits.” 
G.3 “I have serious heart disease.” 
G.4 “InR testing for rest of life. I am blind, hence GP has not suggested me for InR self-testing.”
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